WO2013019889A3 - Anticorps polyclonal bovin spécifique du tnf humain - Google Patents

Anticorps polyclonal bovin spécifique du tnf humain Download PDF

Info

Publication number
WO2013019889A3
WO2013019889A3 PCT/US2012/049207 US2012049207W WO2013019889A3 WO 2013019889 A3 WO2013019889 A3 WO 2013019889A3 US 2012049207 W US2012049207 W US 2012049207W WO 2013019889 A3 WO2013019889 A3 WO 2013019889A3
Authority
WO
WIPO (PCT)
Prior art keywords
polyclonal antibody
antibody specific
human tnf
htnf
polyclonal antibodies
Prior art date
Application number
PCT/US2012/049207
Other languages
English (en)
Other versions
WO2013019889A2 (fr
Inventor
Barbara S. Fox
Eileen F. Bostwick
Daniel E. Tracey
Lisa D. SCHLEHUBER
Michael S. QUESENBERRY
Original Assignee
Avaxia Biologics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/026112 external-priority patent/WO2012141791A1/fr
Application filed by Avaxia Biologics, Inc. filed Critical Avaxia Biologics, Inc.
Priority to AU2012290104A priority Critical patent/AU2012290104A1/en
Priority to CA2843315A priority patent/CA2843315A1/fr
Priority to CN201280042088.2A priority patent/CN103917555A/zh
Priority to BR112014002133A priority patent/BR112014002133A2/pt
Priority to EP12819810.8A priority patent/EP2739650A4/fr
Priority to JP2014524054A priority patent/JP2014527957A/ja
Publication of WO2013019889A2 publication Critical patent/WO2013019889A2/fr
Publication of WO2013019889A3 publication Critical patent/WO2013019889A3/fr
Priority to IL230748A priority patent/IL230748A0/en
Priority to ZA2014/01987A priority patent/ZA201401987B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition qui comporte des anticorps polyclonaux qui se lient spécifiquement au facteur de nécrose tumorale humain (hTNF), les anticorps polyclonaux étant dérivés du sérum, du lait ou du colostrum d'un animal bovin qui a été immunisé par hTNF ou une partie immunogène de celui-ci. L'analyse de spécificité antigénique des anticorps polyclonaux anti-hTNF de l'invention est unique et n'a pas été décrite auparavant pour des anticorps polyclonaux ou monoclonaux anti-hTNF de l'état antérieur de la technique.
PCT/US2012/049207 2011-08-01 2012-08-01 Anticorps polyclonal bovin spécifique du tnf humain WO2013019889A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2012290104A AU2012290104A1 (en) 2011-08-01 2012-08-01 Bovine polyclonal antibody specific for human TNF
CA2843315A CA2843315A1 (fr) 2011-08-01 2012-08-01 Anticorps polyclonal bovin specifique du tnf humain
CN201280042088.2A CN103917555A (zh) 2011-08-01 2012-08-01 人tnf特异性的牛科动物多克隆抗体
BR112014002133A BR112014002133A2 (pt) 2011-08-01 2012-08-01 anticorpo policlonal bovino específico para tnf humano
EP12819810.8A EP2739650A4 (fr) 2011-08-01 2012-08-01 Anticorps polyclonal bovin spécifique du tnf humain
JP2014524054A JP2014527957A (ja) 2011-08-01 2012-08-01 ヒトｔｎｆに特異的なウシポリクローナル抗体
IL230748A IL230748A0 (en) 2011-08-01 2014-01-30 A bovine polyclonal antibody specific for human TNF
ZA2014/01987A ZA201401987B (en) 2011-08-01 2014-02-27 Bovine polyclonal antibody specific for human tnf

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161513872P 2011-08-01 2011-08-01
US61/513,872 2011-08-01
US13/402,527 2012-02-22
PCT/US2012/026112 WO2012141791A1 (fr) 2011-02-22 2012-02-22 Compositions d'anticorps polyclonaux
USPCT/US2012/026112 2012-02-22
US13/402,527 US20120213796A1 (en) 2011-02-22 2012-02-22 Polyclonal antibody compositions

Publications (2)

Publication Number Publication Date
WO2013019889A2 WO2013019889A2 (fr) 2013-02-07
WO2013019889A3 true WO2013019889A3 (fr) 2013-03-28

Family

ID=47629904

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/049207 WO2013019889A2 (fr) 2011-08-01 2012-08-01 Anticorps polyclonal bovin spécifique du tnf humain

Country Status (9)

Country Link
EP (1) EP2739650A4 (fr)
JP (1) JP2014527957A (fr)
CN (1) CN103917555A (fr)
AU (1) AU2012290104A1 (fr)
BR (1) BR112014002133A2 (fr)
CA (1) CA2843315A1 (fr)
IL (1) IL230748A0 (fr)
WO (1) WO2013019889A2 (fr)
ZA (1) ZA201401987B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012141791A1 (fr) * 2011-02-22 2012-10-18 Avaxia Biologics, Inc. Compositions d'anticorps polyclonaux
AU2016335912B2 (en) * 2015-10-05 2023-08-31 Circle33 Llc Antibodies with improved stability to intestinal digestion
GB201701404D0 (en) 2017-01-27 2017-03-15 Micropharm Ltd Therapies for treating inflammatory disorders
GB201812262D0 (en) * 2018-07-27 2018-09-12 Micropharm Ltd Therapies for treating proctitis
GB201812261D0 (en) * 2018-07-27 2018-09-12 Micropharm Ltd Therapies for treating oral mucositis
WO2022103871A1 (fr) * 2020-11-10 2022-05-19 Wyomingv Immune, Inc. Compositions thérapeutiques pour le traitement de la covid-19

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020106372A1 (en) * 1991-03-18 2002-08-08 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
US20080193473A1 (en) * 2005-05-24 2008-08-14 Neovacs Method for Preparing a Stable Immunogenic Product Comprising Antigenic Heterocomplexes of Tnf Alpha and a Carrier Protein
US20100040604A1 (en) * 1996-02-09 2010-02-18 Salfeld Jochen G HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
US20100266607A1 (en) * 2007-10-02 2010-10-21 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1681305A3 (fr) * 1991-03-18 2008-02-27 New York University Anticorps monoclonaux et chimères contre le facteur humain de nécrose de tumeurs
EP2462157B1 (fr) * 2009-08-07 2020-06-17 EMD Millipore Corporation Procédés de purification d une protéine cible d une ou plusieurs impuretés dans un échantillon
HUE027077T2 (en) * 2009-10-15 2016-08-29 Avaxia Biologics Inc Antibody therapy with local activity in the digestive system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020106372A1 (en) * 1991-03-18 2002-08-08 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
US20100040604A1 (en) * 1996-02-09 2010-02-18 Salfeld Jochen G HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
US20080193473A1 (en) * 2005-05-24 2008-08-14 Neovacs Method for Preparing a Stable Immunogenic Product Comprising Antigenic Heterocomplexes of Tnf Alpha and a Carrier Protein
US20100266607A1 (en) * 2007-10-02 2010-10-21 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HYCULTBIOTECH: "MONOCLONAL ANTIBODY TO HUMAN TUMOR NECROSIS FACTOR ALPHA (TNF-alpha) clone 5N.", TECHNICAL DATASHEET, 27 October 2009 (2009-10-27), XP055143532, Retrieved from the Internet <URL:http://www.hycultbiotech.com/doc4371.dx> [retrieved on 20121011] *

Also Published As

Publication number Publication date
IL230748A0 (en) 2014-03-31
CN103917555A (zh) 2014-07-09
EP2739650A4 (fr) 2015-04-01
CA2843315A1 (fr) 2013-02-07
WO2013019889A2 (fr) 2013-02-07
EP2739650A2 (fr) 2014-06-11
AU2012290104A1 (en) 2014-02-13
BR112014002133A2 (pt) 2017-02-21
ZA201401987B (en) 2017-03-27
JP2014527957A (ja) 2014-10-23

Similar Documents

Publication Publication Date Title
PH12017501114A1 (en) Anti-c5 antibodies and methods of use
WO2013043933A3 (fr) Protéines de liaison à un antigène cd27l
WO2013019889A3 (fr) Anticorps polyclonal bovin spécifique du tnf humain
MX359384B (es) Conjunto mejorado de anticuerpos bisespecificos.
WO2017132562A8 (fr) Protéines de liaison à l&#39;antigène se liant à pd-l1
PH12018501282A1 (en) Anti-c5 antibodies and methods of use
PH12014502527B1 (en) St2 antigen binding proteins
WO2013188693A8 (fr) Constructions de liaison à l&#39;antigène pour cd3
MX2023001360A (es) Anticuerpos anti-c5 y metodos de uso.
EA030777B9 (ru) Анти-альфа-синуклеинсвязывающие молекулы
MX354243B (es) Polipeptidos anticuerpos que antagonizan cd40.
WO2011127412A3 (fr) Anticorps st-2 humains solubles et analyses
IN2014CN03936A (fr)
WO2012064792A3 (fr) Complexes protéiques pour la liaison à un antigène, et leurs procédés d&#39;utilisation
MX2013011706A (es) Proteinas novedosas de enlace a antigeno.
NZ604415A (en) Anti-il-23 heterodimer specific antibodies
WO2013063613A3 (fr) Procédés et compositions associés à la neutralisation intracellulaire par une igg
MX365387B (es) Anticuerpos específicos de polipéptido amiloide de islote humano (hiapp) y sus usos.
WO2010121093A3 (fr) Compositions d&#39;anticorps humanisés et procédés de liaison d&#39;acide lysophosphatidique
EA201500502A1 (ru) Связывающие антиген her3 белки, связывающиеся с бета-шпилькой her3
WO2012051282A3 (fr) Diagnostic et thérapie du cancer ciblés sur des protéines de type piwil2 (pl2l)
WO2012110968A3 (fr) Traitement de la maladie de crohn à fistules
TH169581A (th) โปรตีนที่จับกับแอนติเจน st2
PL393508A1 (pl) Rekombinowane przeciwciało monoklonalne o wysokim powinowactwie do antygenu bakteryjnego o natywnej i funkcjonalnej strukturze, sposób otrzymywania przeciwciał monoklonalnych oraz zastosowanie rekombinowanych przeciwciał monoklonalnych

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12819810

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014524054

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2843315

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2012290104

Country of ref document: AU

Date of ref document: 20120801

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012819810

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12819810

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014002133

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014002133

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140128